Nuclear medicine utilizes radioisotopes for application in diagnosis and treatment of diseases. The drugs containing radionuclides are said to be radiopharmaceuticals. Their uses in radiological imaging include Magnetic Resonance Imaging (MRI), Computerized tomography (CT), Positron Emission Tomography (PET) and Single Proton Emission Tomography (SPECT).
North America Nuclear Medicine Market-Market Dynamics
The use of nuclear medicine for diagnostic purposes is gaining importance in North America rapidly. There has been increased use of SPECT, PET, CT and MRI for diagnosis of cardiac diseases, brain diseases, cancer and many others. Nuclear medicine is being used for therapeutic purposes for treatment of Alzheimerdisease, coronary heart diseases, bone metastasis, different medical conditions affecting the thyroid gland, scar tissue removal, and many cancers. Advancements in diagnostic imaging are bringing in more use of nuclear medicine. Nuclear cardiology has gained huge popularity in North America.
Some of the drivers of the North American nuclear medicine market are:
Increasing incidence of cancer, thyroidal diseases, endocrinal diseases, and cardiac ailments
Rise in applications of SPECT and PET with advancement of technology
Growing awareness amongst physicians
Public awareness for better healthcare
The factors restraining the market are:
Short half-life of radiopharmaceuticals
High capital investment required for development
Stringent regulatory guidelines
North Americamarket for nuclear medicine has ample opportunities in the form of:
Increasing imaging technologies
Potential radioisotopes in the pipeline
Increasing neurological applications
Increasing cyclotron-based production
The North American nuclear medicine market has been segmented based on type and application. The segmentation based on type of product has been further divided based on diagnostic market and therapeutic market, wherein, the diagnostics market has been further subdivided into SPECT radioisotopes that include Technetium-993, Thallium-201, Iodine-123, Gallium and PET radioisotopes that include Rubidium-82, Flourine-18, and the therapeutics category has been segmented into Alpha emitters (Radium-223), Beta Emitters(includes Iodine-131, Samarium-153, Lutetium-177, Yttrium-90) and Brachytherapy (includes iodine-125, Cesium-131, Palladium-103, & Iridium-192). The segmentation based on application has been similarly subdivided based on diagnostic and therapeutic application. The diagnostic application includes the application of SPECT and PET in Cardiology, Neurology, Oncology and others. The therapeutic applications include application in Oncology, Thyroid, Endocrinology and various other therapeutic areas.
Based on geography, the market has been segmented into the USA, Canada, and Mexico. Due to high technological advancement coupled with a developed economy, North America has the largest market share globally. In North America, the USA holds the largest market share. The US market is highly supported by the Mo-99 production of NRU reactor (Canada). The nuclear medicine market is slated to grow in the US because of a higher incidence of various forms of cancer and cardiac disorders.
Currently, the diagnostics segment holds the largest share in nuclear medicine market in which again SPECT has the largest share. In the segmentation based on type, the Beta Emitters hold the largest share.
This Report Offers:
Market definition for the North American nuclear medicine market along with identification of key drivers and restraints for the market.
Market analysis for the North American nuclear medicine market, with region-specific assessments and competition analysis.
Identification of factors instrumental in changing the market scenario, rising prospective opportunities and identification of key companies that can influence the market.
Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market share.
Identification and analysis of the macro and micro factors that affect the North American nuclear medicine market on a regional scale.
A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.
1.1 Nuclear medicine procedures
1.2 Major nuclear medicine products
1.3 The S-Curve of nuclear medicine
1.4 Market Matrix
2. EXECUTIVE SUMMARY
3. MARKET OVERVIEW
3.1 Definition of radiopharmaceuticals
4. Market Dynamics
4.1 Market Drivers
4.1.1 Increasing incidents of Cancer and Cardiac ailments
4.1.2 Increasing use of SPECT and PET analysis in radiopharmaceuticals
4.1.3 Increasing awareness of radiopharmaceuticals
4.1.4 Public Awareness
4.1.5 Ready availability of radiopharmaceuticals
4.2 Market Constraints
4.2.1 Shorter half-life of radiopharmaceuticals
4.2.2 High capital investment
4.2.3 Regulatory Guidelines
4.2.4 Reimbursement issues
4.3.1 Potential radioisotopes in pipeline
4.3.2 Increasing neurological applications
4.3.3 Cyclotron based production
4.4.1 Shutdown of Nuclear reactors
5. North America Nuclear Medicine Market Segmentation
5.1 Nuclear Medicine Market, By Type of Products
5.1.1 Diagnostic Market
220.127.116.11 SPECT Radioisotopes
18.104.22.168.1 Technetium-99m (TC-99m)
22.214.171.124.2 Thallium-201 (TL-201)
126.96.36.199.3 Iodine (I-123)
188.8.131.52.4 Gallium -67( Ga-67)
184.108.40.206 PET Radioisotopes
220.127.116.11.2 Rubidium-82 (RB-82)
5.1.2 Therapeutic Market
18.104.22.168 Beta Emitters
22.214.171.124 Alpha Emitters
5.2 North America Nuclear medicine market, By applications
5.3North America Nuclear Medicine - Country Level Analysis
6. COMPETITIVE LANDSCAPE
6.1 Acquisitions and mergers
6.2 New product launches
6.3 Agreements and collaborations
6.4 Market Share Analysis
7. TOP PLAYERS IN THE MARKET
7.2 IBA Group
7.3 Lantheus Medical Imaging
7.4 Triad Isotopes
7.5 Siemens Healthcare (PETNET Solutions)
7.6 NTP Radioisotopes